56607-40-0

Basic information

• Product Name: .alpha.-D-Arabinofuranoside, methyl
• Synonyms: .alpha.-D-Arabinofuranoside, methyl;NSC80725;Methyl a-D-arabinofuranoside;a-D-Arabinofuranoside, Methyl;(2R,3S,4S,5S)-2-(hydroxymethyl)-5-methoxytetrahydrofuran-3,4-diol
• CAS NO: 56607-40-0
• Molecular Formula: C₆H₁₂O₅
• Molecular Weight: 164.16
• Mol File: 56607-40-0.mol
• Article Data: 110

Chemical Properties

• Melting Point: 65-67 °C(Solv: ethyl acetate (141-78-6))
• Boiling Point: 348.7°Cat760mmHg
• Flash Point: 164.7°C
• Appearance: /
• Density: 1.4g/cm³
• PKA: 13.14±0.70(Predicted)
• CAS DataBase Reference: .alpha.-D-Arabinofuranoside, methyl(CAS DataBase Reference)
• NIST Chemistry Reference: .alpha.-D-Arabinofuranoside, methyl(56607-40-0)
• EPA Substance Registry System: .alpha.-D-Arabinofuranoside, methyl(56607-40-0)

Safety Data

• Hazardous Substances Data: 56607-40-0(Hazardous Substances Data)

Usage

General Description

Methyl .alpha.-D-Arabinofuranoside is a chemical compound that is a methylated derivative of the sugar arabinose. It is a white crystalline powder that is soluble in water and commonly used in the field of organic chemistry for various synthetic reactions and as a building block in the synthesis of pharmaceuticals and natural products. It has also been studied for its potential use as an antiviral agent and its ability to inhibit the growth of cancer cells. Methyl .alpha.-D-Arabinofuranoside is an important component in the development of new drug candidates and has potential applications in various medical and scientific fields.

Upstream product

• 67-56-1 methanol 
• 10323-20-3 D-Arabinose 
• 1941-50-0 D-arabinose diethyl dithioacetal 
• 532-20-7 D-arabinofuranose 
• 7473-42-9 methyl tri-O-benzoyl-α-D-arabinofuranoside 
• 28697-53-2 D-arabinopyranose 
• 7647-01-0 hydrogenchloride 
• 40592-40-3 D-arabinose dimethyl dithioacetal 
• 75-36-5 acetyl chloride 
• 79083-42-4 methyl D-arabinofuranoside 
• 4060-35-9 methyl 5-O-trityl-α-D-arabinofuranoside 
• 1114-34-7 D-lyxose 
• 532-20-7 D-lyxose 
• 87-72-9 D-lyxose 

Downstream Products

• 79083-43-5 methyl 2,3,5-tri-O-benzyl-α-D-arabinofuranoside 
• 7473-42-9 methyl tri-O-benzoyl-α-D-arabinofuranoside 
• 201348-41-6 methyl 5-O-benzoyl-α-D-arabinofuranoside 
• 5328-63-2 methyl-β-D-arabinopyranoside 
• 91-09-8 (2S,3S,4R,5R)-2-Methoxy-tetrahydro-pyran-3,4,5-triol 
• 25129-51-5 methyl β-D-arabinofuranoside 
• 164454-52-8 methyl 3,5-O-(tetraisopropylsiloxane-1,3-diyl)-α-D-arabinofuranoside 
• 22224-39-1 methyl 2,3,5-tri-O-acetyl-α-D-arabinofuranoside 
• 83416-40-4 1-α-D-(arabinofuranosyl)-2-nitroimidazole 
• 83416-39-1 1-(2,3,5-tri-O-benzoyl-α-D-arabinofuranosyl)-2-nitroimidazole 
• 83416-41-5 1-(2,3,5-tri-O-benzoyl-β-D-arabinofuranosyl)-2-nitroimidazole 
• 57236-69-8 (3S,4R,5R)-2-acetoxy-5-((benzoyloxy)methyl)tetrahydrofuran-3,4-diyl dibenzoate 
• 131139-02-1 (3aS,5R,6R,6aS)-6-(benzyloxy)-5-((benzyloxy)methyl)-2,2-dimethyltetrahydrofuro[2,3-d][1,3]dioxole 
• 5460-57-1 5-O-benzoyl-1,2-O-isopropylidene-β-D-arabinofuranose 

Relevant articles and documents

Preparation of amino alcohols condensed with carbohydrates: Evaluation of cytotoxicity and inhibitory effect on NO production

This work reports the preparation of several amino alcohols condensed with D-arabinose, D-glucose, and D-galactose derivatives. These compounds were evaluated in vitro for their cytotoxicity and ability to decrease nitric oxide production in J774A.1 cells

MODIFIED OLIGOMERIC COMPOUNDS AND USES THEREOF

The present disclosure provides oligomeric compounds comprising a modified oligonucleotide having at least one stereo-non-standard nucleoside. An oligomeric compound comprising a modified oligonucleotide consisting of 12-30 linked nucleosides, wherein at least one nucleoside of the modified oligonucleotide is a stereo-non-standard nucleoside; and wherein the oligomeric compound is selected from among an RNAi compound, a modified CRISPR compound, and an artificial mRNA compound.

BIOMARKER PANEL TARGETED TO DISEASES DUE TO MULTIFACTORIAL ONTOLOGY OF GLYCOCALYX DISRUPTION

The present disclosure provides biomarkers useful as companion diagnostics for detecting glycocalyx-based disease that is amenable to treatment using compounds designed for improving the condition of the glycocalyx and/or reducing inflammation and/or oxidative damage, as well as related compositions, kits, and methods.